A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam
Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia &
Upjohn Company following a single oral dose (1 x 3 mg extended-release tablet) in healthy
adult volunteers administrated under non-fasting conditions.